Risk factors
Relmada Therapeutics (RLMD) risk factors
Item 1A of every Relmada Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- 2026 10-K risk factors53 risks6 new7 dropped13 reworded
Relmada terminated the development of its primary drug candidate, esmethadone, after the Phase 3 Reliance II study failed to meet its primary efficacy endpoint. The company also dropped psilocybin development for metabolic disease and faced a Nasdaq minimum bid price deficiency. Net operating loss carryforwards increased to approximately $246,410,000 for Federal and $2,719,000 for State.
Filed Mar 19, 2026 - 2025 10-K risk factors54 risks
Relmada Therapeutics paused its primary drug candidate esmethadone and pivoted to early-stage candidates NDV-01 and Sepranolone.
Filed Mar 27, 2025